dUTPase As A Prognostic Marker in Colon Cancer
dUTPase 作为结肠癌的预后标志物
基本信息
- 批准号:6418699
- 负责人:
- 金额:$ 15.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-04-01 至 2004-03-31
- 项目状态:已结题
- 来源:
- 关键词:biomarker clinical research colon neoplasms drug resistance enzyme activity enzyme induction /repression fluoropyrimidine human subject immunocytochemistry metastasis neoplasm /cancer chemotherapy neoplasm /cancer genetics oxidoreductase p53 gene /protein pentosyltransferase phosphomonoesterases polymerase chain reaction prognosis thymidylate synthase
项目摘要
DESCRIPTION (provided by applicant): For more than 40 years, thymidylate
metabolism has been an important biochemical target for widely utilized
anti-cancer agents. Inhibitors of this pathway such as the fluoropyrimidines
and antifolates induce a severe depletion of TTP pools resulting in nucleotide
pool imbalance and cell killing through a process termed "thymineless death."
Investigation of the underlying mechanisms of this process suggest that
aberrant uracil-DNA metabolism may be an important mediator of DNA damage and
cell killing. The broad objectives of this proposal are to better understand
the role of key enzymes involved in dUTP metabolism in modulating
chemosensitivity. In this study, we propose to investigate the prognostic value
of the enzyme deoxyuridine triphosphate nucleotidohydrolase (dUTPase) as a
marker for overall survival and response to fluoropyrimidine-based chemotherapy
in metastatic colon cancer. dUTPase catalyzes the hydrolysis of dUTP to form
dUMP and PPi, thereby eliminating dUTP from the DNA biosynthetic pathway. We
hypothesize that dUTPase overexpression counters the cytotoxic effect of
fluoropyrimidine treatment by limiting the expansion of dUTP pools. Although
there is significant evidence suggesting that uracil-DNA metabolism may be a
critical factor in mediating cytotoxicity, there have been few clinical studies
performed to clarify the role of human dUTPase expression in modulating
chemosensitivity. Specific aim 1 investigates the significance of dUTPase
expression in predicting patient response to fluoropyrimidine-based
chemotherapy and overall survival in metastatic colon cancer. Specific aim 2
compares the prognostic ability of intratumoral dUTPase expression with other
known prognostic markers of colorectal cancer including, thymidylate synthase
(TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and
p53. Clinical analysis of dUTPase expression as a prognostic marker will not
only provide a useful tool for the evaluation and treatment of colon cancer
patients, but will also provide additional insight into the role of aberrant
uracil-DNA metabolism in chemotherapies that inhibit thymidylate metabolism.
描述(由申请人提供):40多年来,胸苷酸
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT D LADNER其他文献
ROBERT D LADNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT D LADNER', 18)}}的其他基金
dUTPase As A Prognostic Marker in Colon Cancer
dUTPase 作为结肠癌的预后标志物
- 批准号:
6620544 - 财政年份:2002
- 资助金额:
$ 15.31万 - 项目类别:
ROLE OF DUTPASE EXPRESSION IN CANCER CHEMOTHERAPY
DuTPase 表达在癌症化疗中的作用
- 批准号:
6626718 - 财政年份:2001
- 资助金额:
$ 15.31万 - 项目类别:
ROLE OF DUTPASE EXPRESSION IN CANCER CHEMOTHERAPY
DuTPase 表达在癌症化疗中的作用
- 批准号:
6489326 - 财政年份:2001
- 资助金额:
$ 15.31万 - 项目类别:
ROLE OF DUTPASE EXPRESSION IN CANCER CHEMOTHERAPY
DuTPase 表达在癌症化疗中的作用
- 批准号:
6266253 - 财政年份:2001
- 资助金额:
$ 15.31万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 15.31万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
$ 15.31万 - 项目类别: